Use of the Advanced Lung Cancer Inflammation Index as a Prognostic Indicator for Patients With Cholangiocarcinoma

Wu, Huasheng; Ding, Fadian; Lin, Meitai; Zheng, Shaojiang; Mei, Zhengzhou; Chen, Shaoqin; Jiang, Chao; Qiu, Huabin; Zheng, Zhenhua; Chen, Youting; Zhao, Peng

doi:10.3389/fsurg.2022.801767

Cited by 7 publications

(7 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Zhang X showed that preoperative ALI was an independent prognostic factor for GC patients undergoing curative gastrectomy [29]. ALI was also revealed to be a prognostic predictor for EC, liver cancer, and cholangiocarcinoma [30][31][32][33]. However, Pian G, Yin CZ, and Barth DA reported that there was no significant difference between ALI and DFS after gastrointestinal surgery [22,28,34].…”

Section: Discussionmentioning

confidence: 99%

“…Pian G, Yin CZ, and Barth DA et al demonstrated that there was no significant difference in ALI between patients receiving CRC surgery or GC surgery [ 22 , 28 , 34 ]. Others thought that a low ALI level would lead to a poor prognosis for gastrointestinal cancer patients [ 21 , 23 – 27 , 29 – 33 ]. Therefore, we aimed to explore the exact prognostic ability of ALI for patients with gastrointestinal cancer undergoing surgery.…”

Section: Introductionmentioning

confidence: 99%

“…Therefore, ALI could reflect the inflammation and nutrition state. Currently, some studies have reported that ALI can predict the survival of many cancers, including CRC [21][22][23][24][25][26][27], GC [28,29], EC [30,31], liver cancer [32], cholangiocarcinoma [33], pancreatic cancer [34,35], and B-cell lymphoma [36].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The advanced lung cancer inflammation index is a prognostic factor for gastrointestinal cancer patients undergoing surgery: a systematic review and meta-analysis

et al. 2023

View full text Add to dashboard Cite

Background The advanced lung cancer inflammation index (ALI) is a comprehensive assessment indicator that can reflect inflammation and nutrition conditions. However, there are some controversies about whether ALI is an independent prognostic factor for gastrointestinal cancer patients undergoing surgical resection. Thus, we aimed to clarify its prognostic value and explore the potential mechanisms. Methods Four databases including PubMed, Embase, the Cochrane Library, and CNKI were used for searching eligible studies from inception to June 28, 2022. All gastrointestinal cancers, including colorectal cancer (CRC), gastric cancer (GC), esophageal cancer (EC), liver cancer, cholangiocarcinoma, and pancreatic cancer were enrolled for analysis. We focused on prognosis most in the current meta-analysis. Survival indicators, including overall survival (OS), disease-free survival (DFS), and cancer-special survival (CSS) were compared between the high ALI group and the low ALI group. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist was submitted as a supplementary document. Results We finally included fourteen studies involving 5091 patients in this meta-analysis. After pooling the hazard ratios (HRs) and 95% confidence intervals (CIs), ALI was found to be an independent prognostic factor for both OS (HR = 2.09, I2 = 92%, 95% CI = 1.53 to 2.85, P < 0.01), DFS (HR = 1.48, I2 = 83%, 95% CI = 1.18 to 1.87, P < 0.01), and CSS (HR = 1.28, I2 = 1%, 95% CI = 1.02 to 1.60, P = 0.03) in gastrointestinal cancer. After subgroup analysis, we found that ALI was still closely related to OS for CRC (HR = 2.26, I2 = 93%, 95% CI = 1.53 to 3.32, P < 0.01) and GC (HR = 1.51, I2 = 40%, 95% CI = 1.13 to 2.04, P = 0.006) patients. As for DFS, ALI also has a predictive value on the prognosis of CRC (HR = 1.54, I2 = 85%, 95% CI = 1.14 to 2.07, P = 0.005) and GC (HR = 1.37, I2 = 0%, 95% CI = 1.09 to 1.73, P = 0.007) patients. Conclusion ALI affected gastrointestinal cancer patients in terms of OS, DFS, and CSS. Meanwhile, ALI was a prognostic factor both for CRC and GC patients after subgroup analysis. Patients with low ALI had poorer prognoses. We recommended that surgeons should perform aggressive interventions in patients with low ALI before the operation.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The advanced lung cancer inflammation index is a prognostic factor for gastrointestinal cancer patients undergoing surgery: a systematic review and meta-analysis

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Interestingly, Wu et al . revealed that ALI outperformed NLR, PLR, monocyte-lymphocyte ratio (MLR), SII, and PNI in predicting OS and DFS in patients with cholangiocarcinoma by using time-dependent ROC analysis [ 16 ]. Thus, the ALI may have a higher discriminating value compared to other biomarkers.…”

Section: Discussionmentioning

confidence: 99%

The prognostic value of the advanced lung cancer inflammation index in patients with gastrointestinal malignancy

et al. 2023

View full text Add to dashboard Cite

Background Systemic inflammation is crucial for the development and progression of cancers. The advanced lung cancer inflammation index (ALI) is considered to be a better indicator of systemic inflammation than current biomarkers. However, the prognostic value of the ALI in gastrointestinal neoplasms remains unclear. We performed the first meta-analysis to explore the association between ALI and gastrointestinal oncologic outcomes to help physicians better evaluate the prognosis of those patients. Methods Eligible articles were retrieved using PubMed, the Cochrane Library, EMBASE, and Google Scholar by December 29, 2022. Clinical outcomes were overall survival (OS), disease-free survival (DFS), progression-free survival (PFS), and cancer-specific survival (CSS). Results A total of 18 articles with 6898 patients were included in this meta-analysis. The pooled results demonstrated that a low ALI was correlated with poor OS (HR = 1.914, 95% CI: 1.514–2.419, P < 0.001), DFS (HR = 1.631, 95% CI: 1.197–2.224, P = 0.002), and PFS (HR = 1.679, 95% CI: 1.073–2.628, P = 0.023) of patients with gastrointestinal cancers. Subgroup analysis revealed that a low ALI was associated with shorter OS (HR = 2.279, 95% CI: 1.769–2.935, P < 0.001) and DFS (HR = 1.631, 95% CI: 1.197–2.224, P = 0.002), and PFS (HR = 1.911, 95% CI: 1.517–2.408, P = 0.002) of patients with colorectal cancer. However, the ALI was not related to CSS in the patients with gastrointestinal malignancy (HR = 1.121, 95% CI: 0.694–1.812, P = 0.640). Sensitivity analysis supported the stability and dependability of the above results. Conclusion The pre-treatment ALI was a useful predictor of prognosis in patients with gastrointestinal cancers.

show abstract

“…Numerous studies have consistently demonstrated the crucial role of inflammatory responses in the development of tumours. In recent years, several indicators reflecting the inflammatory status of the body, such as NLR, PLR, SII, and PNI, have shown correlations with the prognosis of various malignancies [7][8][9][10][11][12][13][14][15][16]. Notably, NLR, PLR, SII, and PNI have exhibited promising results in predicting the prognosis of non-small cell lung cancer and other malignancies.…”

Section: Introductionmentioning

confidence: 99%

The correlation between systemic inflammatory markers and efficiency for advanced gastric cancer patients treated with ICIs combined with chemotherapy

Dong,

Zhao,

et al. 2024

Immunology

View full text Add to dashboard Cite

Currently lacking research to explore the correlation between inflammatory markers and the efficacy of immune checkpoint inhibitors (ICIs) combined with chemotherapy in the treatment of advanced gastric cancer. This study is a retrospective study and included patients with advanced gastric cancer who receiving ICIs combined with chemotherapy from January 2020 to December 2022. We analysed the relationship between systemic inflammatory markers and the efficacy of ICIs combined chemotherapy and constructed a clinical prediction model. A nomogram was constructed based on the results of the bidirectional stepwise regression model. A total of 197 patients were enrolled in the training group, with a median follow‐up period of time 26 months. Kaplan Meier analysis showed that the median OS of patients with low systemic immune‐inflammatory index (SII) and low platelet to lymphocyte ratio (PLR) was superior to those with high SII and PLR. Univariate and multivariate Cox regression analysis showed that SII, NLR, PLR, and N stage as independent prognostic factors for OS. Adding SII to the conventional model improved the predictive ability of the 12‐month OS. A total of 95 patients were included in the validation group, and external validation of the SII‐based nomogram showed favourable predictive performance. Baseline SII, PLR, and N stage may serve as independent predictive factors for survival outcomes in advanced gastric cancer patients undergoing ICIs combined with chemotherapy. The SII‐based nomogram can provide intuitive and accurate prognosis prediction of individual patients.

show abstract

Use of the Advanced Lung Cancer Inflammation Index as a Prognostic Indicator for Patients With Cholangiocarcinoma

Cited by 7 publications

References 29 publications

The advanced lung cancer inflammation index is a prognostic factor for gastrointestinal cancer patients undergoing surgery: a systematic review and meta-analysis

The advanced lung cancer inflammation index is a prognostic factor for gastrointestinal cancer patients undergoing surgery: a systematic review and meta-analysis

The prognostic value of the advanced lung cancer inflammation index in patients with gastrointestinal malignancy

The correlation between systemic inflammatory markers and efficiency for advanced gastric cancer patients treated with ICIs combined with chemotherapy

Contact Info

Product

Resources

About